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Summary
Background Actinic keratosis (AK) is a common premalignant skin lesion that can
progress to cutaneous squamous cell carcinoma (cSCC). Microwave therapy is an
established cancer treatment and has been used for plantar viral warts.
Objectives To evaluate the efficacy and feasibility of microwave as a treatment for
AK.
Methods Stage I was a dose-setting study, in which seven participants had the
dielectric properties of 12 thick and 22 thin AKs assessed for optimization of
the microwave dose used for treatment in Stage II. Stage II was a randomized,
internally controlled trial evaluating 179 AKs in 11 patients (93 treated, 86
untreated controls) on the scalp/forehead or dorsal hand. Participants received
one treatment initially and a repeat treatment to unresolved AKs at week 4.
The response was assessed at six visits over 4 months. The primary outcome
was partial or complete resolution of the treated AKs.
Results A significantly higher proportion of treated AK areas responded than
untreated (90% vs. 15%; P < 0001). Thin AKs were more responsive than
thick AKs. The site did not affect efficacy. Pain was severe, but brief (80%
reported pain lasting ‘a few seconds only’). Adverse effects were minimal (ery-
thema, n = 6; flaking, n = 3; itch, n = 3). All participants who would chose
microwave therapy over their current treatment cited the shorter discomfort
period.
Conclusions Microwave therapy is a portable, safe and effective treatment for
AK. An easy-to-deliver, acceptable therapy for AK is attractive as a prevention
strategy. While these results are promising, a larger randomized controlled
trial is needed against an effective comparator to confirm clinical efficacy and
patient acceptability.
What is already known about this topic?
• Actinic keratoses (AKs) are common precancerous skin lesions.
• Successful treatment of AK can prevent cutaneous squamous cell carcinoma (cSCC).
• Most topical therapies for AK require repeated application over weeks and drive
local skin inflammation, leading to poor compliance.
• An easy-to-deliver and effective treatment for AK, suitable for use in primary care,
could reduce cSCC.
What does this study add?
• Microwave therapy is a feasible, effective treatment for AK.
• Ninety per cent of treated AKs showed full or partial resolution at 120 days post-
treatment.
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• Microwave therapy was painful, but the pain was short-lived (seconds) and this
short discomfort period was cited as the main reason that microwave was preferred
to their current treatment.
Actinic keratosis (AK) is a common precancerous skin lesion
found on light-exposed sites in older fair-skinned individuals
with prevalence rates of 235% in the Dutch population over
50 years of age.1 AKs are precursors to cutaneous squamous
cell carcinoma (cSCC), which has doubled in incidence in a
decade due to ageing populations and increased ultraviolet
radiation exposure.2 The individual risk of progression to cSCC
is low,3 but 65% of cSCCs on the head and neck arise from
AK.4 A double-blind, randomized clinical trial (RCT) of 5%
fluorouracil cream (5-FU) showed a 75% risk reduction for
development of cSCC in the year following treatment [95%
confidence interval (CI) 35–91%; P < 0002].5 This pivotal
study suggests that annual treatment of AK should reduce the
incidence of cSCC. Multiple field treatments for AK exist, such
as 5-FU, imiquimod 5% cream, diclofenac 3% gel, photody-
namic therapy (PDT) and lesion-directed therapy like liquid
nitrogen (cryotherapy).6 Many AK treatments require dedi-
cated application over weeks and drive significant inflamma-
tion. Furthermore, many AK sufferers are elderly and would
find compliance easier with a lesion-directed treatment.
Microwave therapies are established within oncology for
ablative treatment of internal malignancies.7,8 Microwave
energy has shown promise in the treatment of recalcitrant
plantar viral warts.9 This study used a CE-marked microwave
medical device (Swift Microwave Tissue Ablation System,
Emblation Ltd, Alloa, UK). The applicator of the Swift device
delivers microwave energy to the skin at a diameter up to
6 mm and depth of 2–6 mm depending on dosage. The elec-
tromagnetic waves excite water molecules, driving localized
hyperthermia10 and accelerated chemical kinetics.11 Depending
on dose, the treatment can have an ablative destructive or sub-
ablative nondestructive effect.
Here we report a first-in-human, two-stage feasibility study
of microwave therapy for the treatment of AK on the bald
scalp, forehead or dorsal hand.
For Stage I, the objective was to determine the dielectric
properties of AK for optimization of the Swift device micro-
wave parameters to deliver a subablative dose of energy.
Stage II was a single-site, randomized, internally controlled
trial to evaluate the efficacy, long-term resolution, safety and
feasibility of microwave as a treatment.
Materials and methods
Study design and participants
This randomized, internally controlled, feasibility study of
microwave therapy for the treatment of AK (NCT03483935)
was conducted at Ninewells Hospital & Medical School,
Dundee, UK, from January 2018 until April 2019. The study
was co-sponsored by the University of Dundee and NHS Tay-
side (approved December 2017) and was reviewed and
approved by the East of Scotland Research Ethics Service (18/
ES/0008, January 2018). Patients with AKs on the forehead,
bald scalp or dorsal hands were recruited from the dermatol-
ogy department, NHS Tayside. All participants provided writ-
ten informed consent.
Inclusion criteria were age over 18 years with a minimum
of six AKs on both the right and left side of the forehead/
scalp or dorsal hand, able to give informed consent and per-
form study assessments. Exclusion criteria were AKs sited on
the lip or ear, confluent AKs with field change, implantable
cardioverter-defibrillator, pacemaker or other implantable
device, metal implants at the site of microwave treatment,
known intolerance to microwave, unstable comorbidities (in-
cluding cardiovascular disease, active malignancy, inflamma-
tory arthritis) or participation in another interventional study.
Sample-size calculations were based on 100 AKs (50 trea-
ted; 50 untreated, mapped and followed), with on average 10
per participant. In a paired analysis with McNemar’s test, the
power is 80% to detect a difference in proportion > 25%
complete or partial resolution of 033. Repeated measures of
AKs over six visits will give 300 paired measurements. Even
with a smaller mean number of visits (i.e. three), the number
of pairs is increased by the inflation factor to 55 assuming
intraclass correlation coefficient of 005. Hence, with a mean
of three visits (i.e. 150 paired measurements), power would
be 80% to detect a difference of 02 between treated and
untreated in proportion > 25% complete or partial resolution.
Microwave dose
For Stage I, seven participants had the relative permittivity,
conductivity and loss tangent of their AK measured. They did
not receive any microwave dose. A median of five measure-
ments per patient were taken, of which 22 (65%) were for
thin AKs (Olsen grade 1 or 2) and 12 (35%) were for thick
AKs (Olsen grade 3).12 The data allowed calculation of the
energy required to raise the tissue temperature into the subab-
lative region.13 Subablative doses are generally considered to
be below 50 °C.13 A microwave treatment dose of 5 watts
(5W) delivered for 3 s and repeated three times with 20-s
gaps was chosen.
When the 5W dose was delivered to the first two partici-
pants, it caused severe pain and some ulceration/scabbing,
suggesting it was ablative rather than subablative. Modelling
performed by Emblation, the manufacturer of Swift, using
data from the permittivity study and a finite element solution
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of the bioheat transfer equation suggested that 4W for hyperk-
eratotic ‘thick’ AK (Olsen grade 3) and 3W for nonhyperkera-
totic ‘thin’ AK (Olsen grades 1 and 2) would still provide a
therapeutic subablative tissue temperature, with the benefit of
being more tolerable (Table S1; see Supporting Informa-
tion).14 Consequently, the protocol was amended to reflect
this reduction in dose. The protocol change was submitted as
a substantial amendment and approved by the East of Scotland
Research Ethics Service prior to continuing the study.
Study assessments
At the screening visit, participants consenting to Stage II had the
treatment site (scalp/forehead or hands) chosen by the Chief
Investigator based on a clinical decision. AKs were mapped
using an acetate grid and photographed using an agreed proto-
col to aid assessments at later visits. Participants underwent a
general examination to exclude significant comorbidities and
coincidental skin cancer. Participants were randomized to treat-
ment to the left or right side. The randomization system used
was TRuST, a good clinical practice-compliant Tayside Clinical
Trials Unit Interactive Web Response System. No stratification
or minimization was used. One AK on the treatment side was
preselected at screening for biopsy at visit 4. The treatment side
received microwave therapy, with mapped AKs on the contralat-
eral side observed as untreated controls. The probe was placed
in the centre of the AK for each treatment and AKs larger than
the treatment probe were not excluded as it was unclear
whether benefit might extend to adjacent areas of AKs through
local inflammatory or immunological effects. We wished to test
whether AKs larger than the applicator tip would resolve com-
pletely or only partially. Participants were asked to rate their
pain immediately following treatment and 30 min later.
Participants attended for six follow-up visits at 1, 2, 4, 6, 8
and 16 weeks post-microwave treatment. At each visit AKs
were assessed by the Chief Investigator or delegate and scored
as completely resolved, partially resolved or unchanged. Partic-
ipants were asked about local adverse events (itching, stinging,
soreness, redness, flaking, ulceration, pus) and whether these
were mild or severe. Photographs were taken of treated and
control AKs at each visit to aid assessment. There were three
telephone follow-ups on weeks 3, 5 and 7 to assess adverse
events following treatment and biopsy.
A pre-assigned, treated AK was biopsied (4-mm punch
biopsy) at 2 weeks post-treatment (visit 4) for histology and
transcriptome studies.
At week 4, there was the option to repeat treatment to any
previously treated but unresolved AK.
The final visit and AK assessment took place at 4 months
(day 120). Participants were asked to complete a self-assessed
health index about their experience of microwave therapy.
Statistical analysis
The primary outcome, resolution of the treated area of the AK
lesion, was predetermined as either partial (resolution of the
area covered by the microwave probe, but with a rim of per-
sistent AK) or full resolution (complete resolution of the
entire AK) over all time periods. Response was assessed at vis-
its 3 (day 8), 4 (day 15), 6 (day 28), 8 (day 42), 10 (day
60) and 11 (day 120). Mixed-effects logistic regression mod-
els analysed the effect of microwave therapy with random
effects for participant and visit (≤ 6 per participant). Each visit
was analysed as a categorical variable as they were spaced
unequally in time. Variables representing sex, age, skin site
(hand/scalp) and AK subtype (thick/thin) are included as
covariates.
The secondary outcome of long-term response was assessed
using data from visits 10 and 11 (days 60 and 120) only.
Again, nonlinear models were utilized with random effects for
participant and visit (≤ 2 per participant) and covariates for
sex, age, skin site (hand/scalp) and AK subtype (thick/thin).
Pain during and following treatment were secondary out-
comes. SAS Enterprise Guide software (version 61, SAS Insti-
tute Inc., Cary, NC, USA) was used for all statistical analyses.
Results
Study participants
Eleven participants, seven male and four female, gave
informed consented and were randomized to Stage II. The
Consort flow diagram is illustrated in Figure 1. Participant
demographics and cancer history are shown in Table 1. Ten
of 11 (91%) participants had received prior treatments with
both cryotherapy and 5-FU cream. Additional treatments in
order of frequency were 3% diclofenac gel (Solaraze) (64%),
5% imiquimod cream (Aldara) (55%), ingenol mebutate gel
(Picato) (45%), surgery (45%), PDT (36%) and 5-FU 05%
and salicylic acid 10% topical solution (Actikerall) (27%) as
detailed in Table S2 (see Supporting Information).
Microwave dose
Following permittivity studies (Stage I), the microwave dose
was chosen and delivered as described in Materials and meth-
ods. The first two participants in Stage II received a 5W dose
for 3 s repeated three times to each treated AK, but the subse-
quent nine participants received 3W 3-s doses to thin AKs
(Olsen grades 1 & 2) and 4W 3-s doses to thick AKs (Olsen
grade 3).
Treatments and biopsies
Eleven participants were randomized to the RCT and 179 AKs
(93 treated, 86 untreated) assessed (Figure 1). All participants
completed treatment as planned and at follow-up visit 10 (day
60) one participant’s treated AKs could not be assessed due to
an unrelated hospital admission (the hand was bandaged for
an in situ cannula). Ten participants underwent a second treat-
ment on day 28 (visit 6), with 51 of 93 (55%) treated AKs
receiving a second treatment. One of the participants who had
© 2020 The Authors. British Journal of Dermatology
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received the 5W dose declined repeat treatment due to pain.
All biopsies of pre-assigned AKs were undertaken at day 15, 2
weeks after the first treatment.
Biopsies of AKs treated with 5W (n = 2) showed dermal
fibrosis, mixed acute and chronic inflammatory infiltrate, and
some reactive squamous metaplasia of eccrine ducts. Any epi-
dermal dysplasia was mild. Six of the remaining nine AK
biopsies showed some inflammation with mild-to-moderate
epidermal dysplasia in the majority, although three of nine
noted moderate-to-severe epidermal dysplasia consistent with
persistent AK.
Effectiveness of treatment
Overall response rates (including both partial and complete
resolution) for treated AKs were 78% at visit 3 (day 8), rising
to 90% at visit 11 (day 120) (Table 2, Figure 2), compared
with 2% at visit 3 and 15% at visit 11 for untreated AK. The
results of a nonlinear repeated measures model of resolution
Assessed for objective 1 (n = 93 AKs) 
Assessed for objective 2 (n = 11 participants) 
Lost to follow-up (n = 0) 
Discontinued intervention (n = 0) 
Treated AKs (n = 93)
Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0) 
Discontinued intervention (n = 0) 
Control AKs (n = 86) 
Assessed for objective 1 (n = 86 AKs) 
Assessed for objective 2 (n = 11 participants) 
Allocation
Assessment
Follow-up
Participants randomized to treatment side  
(n = 11)
Assessed for eligibility 
(participants) (n = 21)
Excluded participants (n = 10) 
• Not meeting inclusion criteria (n = 6) 
• Declined to participate (n = 4) 
Enrolment
Figure 1 CONSORT diagram.
Table 1 Baseline characteristics for 11 participants
Variable Statistic/status Summary
Age (years) n 11
Mean (SD) 78 (6)
Median 78
Range 62–88
Sex Female 4 (36%)
Male 7 (64%)
History of skin cancer Yes 10 (91%)
No 1 (9%)
History of other cancer Yes 0 (0%)
No 11 (100%)
© 2020 The Authors. British Journal of Dermatology
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found a significantly higher proportion of AKs treated with
microwave therapy to have fully or partially resolved com-
pared with untreated control AKs (odds ratio 154, 95% CI
75–317, P < 0001, Table 3). The magnitude of the odds
ratio reflects the sustained resolution of treated AKs across all
visits (Table 2, Figure 2). The photographs in Figure 3 show
examples of partial and complete resolution.
The type of AK (thick vs. thin) was associated with
response (Table 3, Figure 4). Thin AKs had a higher response
rate than thick AKs, but similarly, in the untreated group, thin
AKs were more likely to resolve spontaneously (Figure 4).
Participant-reported pain and safety
Most participants reported ‘moderate’ or ‘severe’ pain during
treatment and all participants reported no pain after 30 min
(Table 4). Eighty per cent of participants reported pain lasting
a few seconds only; 20% reported pain lasting up to 5 min.
Redness (n = 6), flaking (n = 3) and itching (n = 3) were
reported as adverse events. There were no unexpected or seri-
ous side-effects. Most participants preferred microwave or had
no preference when comparing their experience of microwave
with previous treatments (Table 5).
Table 2 Summary for primary endpoint by visit for AK lesions
Visit
Treated Not treated
Lesions, n n (%) Resolution Lesions, n n (%) Resolution
Visit 3 (day 8) 93 73 (78) 4 CR, 69 PR 86 2 (2) 1 CR, 1 PR
Visit 4 (day 15) 93 73 (78) 7 CR, 66 PR 86 7 (8) 1 CR, 6 PR
Visit 6 (day 28) 93 86 (92) 20 CR, 66 PR 86 9 (10) 2 CR, 7 PR
Visit 8 (day 42) 93 86 (92) 23 CR, 63 PR 86 9 (10) 3 CR, 6 PR
Visit 10 (day 60)a 84 81 (96) 41 CR, 40 PR 86 11 (13) 5 CR, 6 PR
Visit 11 (day 120) 93 84 (90) 39 CR, 45 PR 86 13 (15) 6 CR, 7 PR
aThe clinical investigator was unable to assess nine treated AKs on one participant at visit 10 due to the participants’ hand being cannulated
for other medical treatment during an unrelated inpatient admission. CR, complete resolution; PR, partial resolution
Figure 2 Percentage of treated actinic keratoses (AKs) that responded by week.
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Discussion
This first-in-human study suggests that microwave therapy
might be a promising treatment for AK, with 90% of AKs
showing resolution of the treated area at 120 days post treat-
ment (Table 2). This was highly significant (P < 0001) and
was more effective for thin than for thick AKs (P < 0001), as
has been noted with most other therapies, including PDT.15,16
Our study included hyperkeratotic AKs and acral sites, both of
which are associated with higher rates of treatment failure.6,17
AKs larger than the microwave probe diameter were not
excluded in this study. Many larger AKs demonstrated com-
plete resolution of the central area under the applicator tip,
but with a rim of persistent AK outside this treatment area
and these lesions were recorded as a partial response despite
resolution of the treated area. Therefore, rates of complete
Table 3 Odds ratios (OR) from the mixed model for actinic keratosis
response
Variable OR 95% CI P-value
Treatment vs. placebo 154 75–317 < 0001
Visit < 0001
Visit (3 vs. 11) 025 01–058
Visit (4 vs. 11) 033 014–075
Visit (6 vs. 11) 087 042–178
Visit (8 vs. 11) 087 042–179
Visit (10 vs. 11) 125 065–242
Age (+ 1 year) 103 097–108 033
Sex: female (ref, male) 056 026–121 014
Scalp site (ref, hand) 168 078–361 018
Thin subtype (ref, thick) 347 18–666 < 0001
CI, confidence interval
Figure 3 Photographs at visit 1 (screening visit) and visit 11 (day 120) show improvement following microwave therapy for selected
hyperkeratotic actinic keratoses [marked by circles (n = 6)]. CR, complete resolution; NR, no resolution PR, partial resolution.
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2020)
6 Microwave therapy for precancerous AKs, D.N. Jackson et al.
resolution in this study appear to be relatively modest, with
42% of AKs showing complete resolution at 120-day follow-
up. In future studies, adopting a stepwise overlapping delivery
of treatment across the whole surface of the AK might lead to
higher rates of complete resolution. This approach has been
used successfully for plantar warts.9 Seven per cent of
untreated AKs had spontaneously resolved by visit 11, which
is similar to that reported in other studies18 and demonstrates
the importance of an internal control.
The participants in this study were representative of the
patient population with AK, with a median age of 78 years
and majority male (64%). An increased prevalence of AK with
advancing age and male sex has been noted in both primary19
and secondary care.20 Importantly, there was no difference in
response with sex, age or skin site. In contrast, many alterna-
tive therapies have demonstrated reduced efficacy on acral
sites.6,17
One week after initial treatment (visit 3), 78% of AKs
showed a response, which rose to 92% by 4 weeks (visit 6),
which may suggest that induction of an immune response
promotes clearance. A similar effect was seen with treatment
to plantar warts.9 This implies that there may be a possibility
of ‘field’ benefit with microwave therapy and in this study, as
demonstrated in Figure 3, the post-treatment appearance did
show a general improvement in addition to specific resolution
(partial or complete) of individual AKs. Nonetheless, micro-
wave therapy should be considered a lesion-directed therapy
rather than a field-directed therapy and any subsequent exami-
nation in a head-to-head comparison with current AK thera-
pies should include a cryotherapy arm as well as a topical 5-
FU or imiquimod arm.
Figure 4 Summary tree.
Table 4 Summary of pain during treatment
Variable
Visit 2
participants, n (%)
Visit 6
participants, n (%)
Pain during treatment
Mild 7 (8) 5 (10)
Moderate 32 (34) 27 (53)
Severe 54 (58) 19 (37)
Duration of pain
Few seconds 7 (64) 8 (80)
Up to 5 min 2 (18) 2 (20)
Up to 10 min 1 (9) 0 (0)
Up to 20 min 1 (9) 0 (0)
Still sore at 30 min 0 (0) 0 (0)
Table 5 Patient experience
Week 10 Week 11
Choice of another AK treatment
Prior treatment 1 2
Microwave 4 6
No preference 6 3
Reason for choicea
Less pain 1 1
Shorter discomfort period 3 6
Fewer side-effects 3 4
Other 2 1
Pain if second treatment
More painful 1 0
Less painful 5 5
No difference 4 5
Not applicable 1 1
Worry about treatment
Yes 0 1
No 11 10
AK, actinic keratosis
aNot all participants gave a reason for their choice and some par-
ticipants chose more than one reason for their choice
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The main side-effect was pain. The first two participants,
treated with 5W doses, found the treatment very painful and
one participant declined repeat treatment at 4 weeks. This
higher dose appears more efficacious with 100% of AKs show-
ing a response to the 5W dose compared with 88% with the
3W or 4W dose (Table S3; see Supporting Information). All
participants were included in the overall statistical assessment.
The subsequent lower doses (3W or 4W), delivered after an
amendment to the protocol, were well tolerated. Participants
described pain as ‘minimal’ initially, but ‘very painful’ for the
final 1 s of treatment. While 58% of participants described
pain as severe at the first treatment, this reduced to 37% with
the second treatment, and most (80%) reported the pain as
lasting a few seconds only (Table 4). This reduction may be
due to greater expectation with repeat treatment. All partici-
pants eligible for the study completed it and none of the par-
ticipants who received the lower microwave dose with the
revised protocol declined a second treatment, suggesting that
this was tolerable, despite treatment of up to 10 AKs per treat-
ment. Rarely did pain last longer than 5 min (Table 4) and
severe pain never lasted more than a few seconds. This short
duration undoubtedly makes the treatment more tolerable.
When surveyed about their patient experience on day 120, six
patients would choose microwave treatment over their current
AK therapy, and all cited a shorter discomfort period as a rea-
son (Table 5). Pain is common with existing treatments such
as cryotherapy and PDT; however, patients often accept this if
a treatment is effective.21
Other adverse events following microwave treatment were
minimal [erythema (n = 6), flaking (n = 3) and itch (n = 3)].
This contrasts favourably with treatments like 5-FU or 5%
imiquimod cream, which cause significant inflammation
including swelling, erosions, crusting and blistering.22 Diclofe-
nac 3% in hyaluronic acid gel causes less severe local skin
reactions23 and is a treatment favoured by general practice in
the UK.24,25 However, its long treatment duration (3 months)
may reduce compliance.
There were study limitations. This was a small study with 11
participants, but analysis was per AK and 179 AKs were
assessed, increasing the power. Participants were recruited from
secondary care so had relatively severe AK. Sufficient ‘thick’ and
‘thin’ AKs were treated to analyse these subgroups indepen-
dently. While the side to receive treatment was randomized, the
assessors were not blinded. Blinding was not feasible as only
two clinicians were involved in both treatment delivery and fol-
low-up. Furthermore, erythema from the treatment and, at later
visits, the biopsy scar, would reveal the treatment side. As a
first-in-human study, the effects of treatment on AKs were not
known. As such, both partial and complete resolution of indi-
vidual AKs were assessed and we have reported the response
rates by complete, partial or none in Table 2 and Figure 2. Due
to the lack of overlapping or stepwise treatment over the entire
surface of larger AKs, this study may underestimate the potential
for complete resolution. There was minimal missing data.
The microwave device used is portable and safe and does
not require the impractical storage infrastructure of
cryotherapy. Minimal training is needed and multiple lesions
can be treated in a single session. These factors make it partic-
ularly suitable for primary care where AKs are prevalent. Of
2844 consecutive patients enrolling with a general practitioner
in Switzerland, 23% had AK.19 Given the mounting evidence
that treatment of AK can prevent cSCC,5 a treatment that can
be delivered in primary care, possibly when the patient is
attending for another reason, may be effective at reducing the
burden of cSCC. While these results are promising, a larger
RCT is needed against an effective lesion-directed comparator
such as cryotherapy, as well as a field treatment, to confirm
clinical efficacy and patient acceptability.
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